HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Survival in primary congenital pulmonary lymphangiectasia with hydrops fetalis.

Abstract
The recent advances in neonatal and pediatric intensive care have changed the outcome of patients with congenital pulmonary lymphangiectasia of different types, including those cases with early neonatal symptoms. However, the patients who present the most severe form of the disease, manifested by in utero hydrops (including those treated by in utero thoracoamniotic shunting to relieve the mediastinal compression), have had an unvaryingly fatal ending in all published reports, with most cases dying before birth, and the few born alive dying during the first days of life. We present a patient with primary congenital pulmonary lymphangiectasia complicated by hydrops fetalis, who was treated in utero, survived the neonatal period after intensive medical and surgical support, and was discharged home at the age of 2 months. She is currently 6 months old, and has minimal signs or symptoms of chronic lung disease. The different aspects of the management of congenital pulmonary lymphangiectasia are discussed in this report, together with a review of the literature.
AuthorsPablo Laje, R Douglas Wilson, Marta Guttenberg, Kenneth W Liechty
JournalFetal diagnosis and therapy (Fetal Diagn Ther) Vol. 24 Issue 3 Pg. 225-9 ( 2008) ISSN: 1421-9964 [Electronic] Switzerland
PMID18753762 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright 2008 S. Karger AG, Basel.
Topics
  • Adult
  • Female
  • Fetal Diseases (diagnostic imaging, therapy)
  • Humans
  • Hydrops Fetalis (diagnostic imaging, therapy)
  • Lung Diseases (complications, diagnostic imaging, pathology, therapy)
  • Lymphangiectasis (complications, diagnostic imaging, pathology, therapy)
  • Lymphatic Vessels (pathology)
  • Pregnancy
  • Treatment Outcome
  • Ultrasonography, Prenatal

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: